Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

Bibliographic Details
Main Author: Frontiers Editorial Office
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
KRAS mutation G12C
inhibitor 9
castration-resistant prostate cancer
drug resistance
metastasis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.707608/full
id doaj-aeb1047354834ddf994037f3cb4d469e
record_format Article
spelling doaj-aeb1047354834ddf994037f3cb4d469e2021-05-31T14:23:04ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.707608707608Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling PathwayFrontiers Editorial Officehttps://www.frontiersin.org/articles/10.3389/fonc.2021.707608/fullKRAS mutation G12Cinhibitor 9castration-resistant prostate cancerdrug resistancemetastasis
collection DOAJ
language English
format Article
sources DOAJ
author Frontiers Editorial Office
spellingShingle Frontiers Editorial Office
Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
Frontiers in Oncology
KRAS mutation G12C
inhibitor 9
castration-resistant prostate cancer
drug resistance
metastasis
author_facet Frontiers Editorial Office
author_sort Frontiers Editorial Office
title Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
title_short Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
title_full Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
title_fullStr Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
title_full_unstemmed Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway
title_sort retraction: inhibitor 9 combined with androgen deprivation therapy or chemotherapy delays the malignant behavior of castration-resistant prostate cancer through k-ras/plcϵ/pkcϵ signaling pathway
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-05-01
topic KRAS mutation G12C
inhibitor 9
castration-resistant prostate cancer
drug resistance
metastasis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.707608/full
work_keys_str_mv AT frontierseditorialoffice retractioninhibitor9combinedwithandrogendeprivationtherapyorchemotherapydelaysthemalignantbehaviorofcastrationresistantprostatecancerthroughkrasplcepkcesignalingpathway
_version_ 1721418861557841920

Similar Items